PatenSee builds a contactless optical imaging platform that uses embedded AI to scan dialysis vascular access sites and analyze images in real time, with scans reportedly taking one to two minutes. The system is designed to detect potential complications earlier—PatenSee cites possible detection 30 to 60 days before clinical manifestation—while avoiding physical contact to reduce infection risk. The company is running a clinical pilot with Henry Ford Health and the MSU Innovation Hub to collect real-world data and validate usability in clinical workflows. PatenSee intends to pursue FDA clearance later this year and targets a commercial launch in early 2027, alongside establishing a U.S. headquarters in Michigan. Financially, the company closed a $2 million Seed round led by Michigan Rise and receives additional support from the Michigan Israel Business Accelerator. The product roadmap and go-to-market plan are focused on robust clinical validation, regulatory readiness, and integration into dialysis care pathways.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2026